600713.SS SHH
NanJing Pharmaceutical Company Limited
1W: -0.4%
1M: -4.4%
3M: -1.2%
YTD: -10.7%
1Y: -4.4%
3Y: +2.9%
5Y: +16.0%
¥5.00 ($0.75)
+0.06 (+1.21%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$53.7B
+0.2% ▲
5Y CAGR: +7.6%
Gross Profit
$3.4B
+2.0% ▲
5Y CAGR: +6.5%
Operating Income
$1.0B
+1.6% ▲
5Y CAGR: +14.1%
Net Income
$571M
-1.2% ▼
5Y CAGR: +10.5%
EPS (Diluted)
$0.44
-2.2% ▼
5Y CAGR: +5.9%
EBITDA
$1.7B
+3.4% ▲
5Y CAGR: +16.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $39.8B | $45.1B | $50.2B | $53.6B | $53.7B |
| YoY Growth | +7.2% | +13.3% | +11.3% | +6.7% | +0.2% |
| Cost of Revenue | $37.3B | $42.2B | $47.0B | $50.3B | $50.3B |
| Gross Profit | $2.5B | $2.9B | $3.3B | $3.3B | $3.4B |
| Gross Margin | 6.4% | 6.5% | 6.5% | 6.2% | 6.3% |
| R&D Expenses | $16M | $21M | $27M | $36M | $31M |
| SG&A Expenses | $366M | $534M | $609M | $595M | $589M |
| Operating Expenses | $1.4B | $1.6B | $1.8B | $2.3B | $2.3B |
| Operating Income | $676M | $846M | $1.3B | $1.0B | $1.0B |
| Operating Margin | 1.7% | 1.9% | 2.6% | 1.9% | 1.9% |
| Interest Expense | $372M | $455M | $447M | $545M | $529M |
| Income Before Tax | $678M | $839M | $906M | $978M | $1.0B |
| Tax Expense | $208M | $228M | $190M | $265M | $260M |
| Net Income | $376M | $505M | $596M | $578M | $571M |
| Net Margin | 0.9% | 1.1% | 1.2% | 1.1% | 1.1% |
| EPS (Diluted) | $0.36 | $0.49 | $0.48 | $0.45 | $0.44 |
| EBITDA | $862M | $1.5B | $1.6B | $1.6B | $1.7B |
| Shares Outstanding | 1.04B | 1.04B | 1.25B | 1.29B | 1.30B |